Pacira BioSciences (NASDAQ:PCRX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.
Several other brokerages have also commented on PCRX. HC Wainwright lifted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Needham & Company LLC decreased their target price on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $26.44.
Get Our Latest Research Report on Pacira BioSciences
Pacira BioSciences Stock Down 2.9%
Shares of Pacira BioSciences stock traded down $0.77 on Friday, reaching $25.97. The company's stock had a trading volume of 431,551 shares, compared to its average volume of 972,803. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $29.95. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -12.79 and a beta of 0.56. The firm's fifty day simple moving average is $25.53 and its two-hundred day simple moving average is $23.32.
Insider Buying and Selling
In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the sale, the senior vice president now owns 59,564 shares of the company's stock, valued at approximately $1,561,172.44. This trade represents a 8.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.40% of the stock is owned by insiders.
Institutional Trading of Pacira BioSciences
A number of institutional investors have recently made changes to their positions in PCRX. State of Wyoming lifted its position in Pacira BioSciences by 8.0% during the 4th quarter. State of Wyoming now owns 6,566 shares of the company's stock worth $124,000 after acquiring an additional 487 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after purchasing an additional 513 shares in the last quarter. US Bancorp DE increased its stake in Pacira BioSciences by 31.0% during the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock worth $56,000 after buying an additional 537 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Pacira BioSciences by 3.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after buying an additional 794 shares in the last quarter. Finally, Sterling Capital Management LLC grew its position in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after purchasing an additional 1,208 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
